Biohaven Pharmaceutical enrolls first patient in Phase 3 trial of troriluzole
Biohaven Pharmaceutical announced that it has enrolled its first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder. Biohaven expects to enroll approximately 372 patients in this randomized, double-blind, placebo-controlled trial across approximately 50 sites in the United States. Researchers will evaluate acute symptomatic treatment with troriluzole in patients with a diagnosis of generalized anxiety disorder. The primary outcome measure is the change in a patient's score on the Hamilton Anxiety Rating Scale, a scale designed to assess the severity and type of symptoms in patients with GAD. The trial will also assess the safety, tolerability and pharmacokinetics of troriluzole.